Category Archive for: ‘Embeda’

FDA Approves Embeda™ For Management of Moderate to Severe Chronic Pain

August 13, 2009PRNewsWIre King Pharmaceuticals®, Inc. (NYSE:KG) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA™ …

Read More